Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Alley

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Journal of the American Veterinary Medical Association|August 15, 1990
Efficacy of intramammary treatment in unbred and primigravid dairy heifersP Trinidad, S C Nickerson, T K Alley, et al.
Journal of Bacteriology|November 12, 2002
Degradation of a Caulobacter soluble cytoplasmic chemoreceptor is ClpX dependentIsabel Potocka, Melanie Thein, Magne ØSterås, et al.
Expert Opinion on Investigational Drugs|January 25, 2007
Recent progress on the topical therapy of onychomycosisMichael R K Alley, Stephen J Baker, Karl R Beutner, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosisJason E Cummings, Christopher S Lunde, M R K Alley, et al.
FEBS Letters|August 23, 2011
Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing capJaya Sarkar, Weimin Mao, Tommie L Lincecum, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilliRodrigo E Mendes, M R K Alley, Helio S Sader, et al.
Arxiv|April 24, 2024
GPU-Accelerated RSF Level Set Evolution for Large-Scale Microvascular SegmentationMeher Niger, Helya Goharbavang, Taeyong Ahn, et al.
Scientific Reports|October 22, 2025
Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomalleiJason E Cummings, Danara Flores, Vincent E Guglielmi, et al.
Drugs of Today (Barcelona, Spain : 1998)|November 20, 2015
Tavaborole topical solution, 5% for the treatment of toenail onychomycosisL T Zane, J Plattner, S Chanda, et al.
Journal of Molecular Biology|May 12, 2009
Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaborolesElena Seiradake, Weimin Mao, Vincent Hernandez, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Journal of the American Veterinary Medical Association|August 15, 1990
Efficacy of intramammary treatment in unbred and primigravid dairy heifersP Trinidad, S C Nickerson, T K Alley, et al.
Journal of Bacteriology|November 12, 2002
Degradation of a Caulobacter soluble cytoplasmic chemoreceptor is ClpX dependentIsabel Potocka, Melanie Thein, Magne ØSterås, et al.
Expert Opinion on Investigational Drugs|January 25, 2007
Recent progress on the topical therapy of onychomycosisMichael R K Alley, Stephen J Baker, Karl R Beutner, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosisJason E Cummings, Christopher S Lunde, M R K Alley, et al.
FEBS Letters|August 23, 2011
Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing capJaya Sarkar, Weimin Mao, Tommie L Lincecum, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilliRodrigo E Mendes, M R K Alley, Helio S Sader, et al.
Arxiv|April 24, 2024
GPU-Accelerated RSF Level Set Evolution for Large-Scale Microvascular SegmentationMeher Niger, Helya Goharbavang, Taeyong Ahn, et al.
Scientific Reports|October 22, 2025
Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomalleiJason E Cummings, Danara Flores, Vincent E Guglielmi, et al.
Drugs of Today (Barcelona, Spain : 1998)|November 20, 2015
Tavaborole topical solution, 5% for the treatment of toenail onychomycosisL T Zane, J Plattner, S Chanda, et al.
Journal of Molecular Biology|May 12, 2009
Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaborolesElena Seiradake, Weimin Mao, Vincent Hernandez, et al.
Pageof 5